

\*\*\*New release November 2009\*\*\*

## DiseaseINFOPACK: *Clostridium difficile* in China (CAT: VADIP017)

<b>Proposal No/#PO</b>	:	<b>[Enter client specific #PO]</b>
<b>Product Name</b>	:	Comprehensive literature review/analysis of <i>Clostridium difficile</i> associated disease in China
<b>Project Initiation Date</b>	:	n/a
<b>Billable days</b>	:	n/a
<b>Initiator(s)</b>	:	[Enter client name, function and address]
<b>Therapeutic Area</b>	:	<i>Nosocomial infections</i>
<b>Product (if applicable)</b>	:	<b>CAT No:</b> VADIP017, published November 2009

## Background

*Clostridium difficile* (C.diff) is a Gram-positive bacterium, which in vulnerable hospitalized patients can cause gastrointestinal infections (CDAD). Outcomes range from mild uncomplicated diarrhea to severe-complicated disease where patients experience fever, tachycardia and pseudomembranous colitis. Risk factors for C.diff infections are >65 yrs of age, hospitalization, severe underlying illness coupled with chronic antibiotic therapy.

While information and literature pertaining to C.diff epidemiology is accumulating in Western markets, a lot less is known in large emerging nations such as China. Information is required to understand whether the extent of disease epidemiology and associated dynamics is similar to the West, and which steps need to be taken in order to accurately assess current disease burden.

This **DiseaseINFOPACK** is a comprehensive up-to-date review of current literature, also capturing the viewpoint of local physicians. It is designed to support the information gathering of commercial manufacturers of C.diff related therapies and immunotherapies who may wish to consider building a market development strategy in this region. The report has been written by a highly experienced expert author (Tenured US Professor level, MD/Ph.D) who trained in China and is knowledgeable in C.diff, vaccinology/local issues. The author also currently operates active C.diff research in China.

**PRODUCT CONTENTS:**

**Published November 2009 (CAT No: VADIP017)**

Executive summary  
Introduction  
Research Methodology  
About the Author  
Awareness of C.diff in China  
Incidence and disease trends  
Part I: Reports published in international English journals  
Part II: Reports published in Chinese language journals  
Part IIa: C.diff infection incidence among general inpatient populations  
Part IIb: C.diff infection incidence among specific inpatient populations  
Part III: Summary viewpoint(s) after discussion with local physicians  
C.diff relapse rate and China  
C.diff severity and China  
C.diff risk factors and China – underlying comorbidities  
C.diff risk factors and China – use of broad spectrum antibiotics  
C.diff risk factors and China – host immune status  
C.diff risk factors and China – residence in nosocomial setting  
C.diff and current treatments in China  
C.diff and endemic strains in China  
Comments on economic burden of C.diff infection in China  
Identified local and national experts in C.diff and/or hospital infections  
Bibliography  
About VacZine Analytics  
Disclaimer

**PAGES: ~35 MS Powerpoint slides, fully referenced/sourced. Available in .pdf form**

**PROJECT METHODOLOGY:**

**VacZine Analytics** has conducted a comprehensive secondary research to review all available information regarding *Clostridium difficile* in China. Source materials used are English and Chinese literature articles, government websites, medical bodies and associations, conference proceedings/attendance etc. The author has also participated in discussions with local physicians regarding issues related to *Clostridium difficile* infection.

**PRODUCT PRICE:**

**VacZine Analytics** will grant a [enter region] license to [enter client name], for the price of:


- o USD \$4895.00/ GBP £3265.00 (Region license)\*

\*A region is North America, Europe or ROW

For orders in the UK, VAT at 15% will be added to final invoice total

#### HOW TO ORDER:

To order please contact your region account manager or order direct at [orders@vaczine-analytics.com](mailto:orders@vaczine-analytics.com)  
This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728  
**VacZine Analytics (R)** and the “**spiral logo**” are UK Registered Trademarks, 2009

#### BIBLIOGRAPHY:

Due to nature of this product the bibliography is proprietary to **VacZine Analytics** and available only to purchasing clients

**TERMS and CONDITIONS:**

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client’s cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on-line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company’s obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. **Force Majeure:** The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, influenza pandemic, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request or at [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics  
Of Assay Advantage Ltd**

Warren House  
Bells Hill  
Bishops Stortford  
Herts  
CM23 2NN  
United Kingdom  
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926  
E-mail: [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728  
**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009

## About VacZine Analytics:

**VacZine Analytics** is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website [www.vacZine-analytics.com](http://www.vacZine-analytics.com)

**VacZine Analytics (R)** is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

**VacZine Analytics (R)** and “the spiral logo” are UK Registered Trademarks, 2009



**VacZine Analytics**<sup>®</sup>

Bringing life to vaccine strategy...

Bringing life to vaccine strategy...

[www.vacZine-analytics.com](http://www.vacZine-analytics.com)

Warren House, Bells Hill, Bishops Stortford, Herts CM23 2NN, United Kingdom **Tel.** +44 (0) 1279 654514 **e-mail:** [info@vacZine-analytics.com](mailto:info@vacZine-analytics.com)

